C4 Therapeutics Inc Forecast, price target & analysts
C4 Therapeutics Inc Target price 2025 - Analyst rating & recommendation
C4 Therapeutics Inc Classifications & Recommendation:
C4 Therapeutics Inc Price Target
| Target Price | $10.20 |
| Price | $2.50 |
| Potential |
308.00%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target C4 Therapeutics Inc 2026 .
The average C4 Therapeutics Inc target price is $10.20.
This is
308.00%
register free of charge
$30.45
1,118.00%
register free of charge
$6.06
142.40%
register free of charge
|
|
| A rating was issued by 13 analysts: 12 Analysts recommend C4 Therapeutics Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the C4 Therapeutics Inc stock has an average upside potential 2026 of
308.00%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 35.58 | 28.65 |
| 71.39% | 19.49% | |
| EBITDA Margin | -324.23% | -395.26% |
| 50.92% | 21.91% | |
| Net Margin | -296.01% | -410.48% |
| 53.62% | 38.67% |
8 Analysts have issued a sales forecast C4 Therapeutics Inc 2025 . The average C4 Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an C4 Therapeutics Inc EBITDA forecast 2025. The average C4 Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 C4 Therapeutics Inc Analysts have issued a net profit forecast 2025. The average C4 Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.52 | -1.59 |
| 43.07% | 4.61% | |
| P/E | negative | |
| EV/Sales | 1.76 |
9 Analysts have issued a C4 Therapeutics Inc forecast for earnings per share. The average C4 Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
C4 Therapeutics Inc...
Current C4 Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays |
Locked
➜
Locked
|
Locked | Sep 23 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Sep 23 2025 |
| Stephens & Co. |
Locked
➜
Locked
|
Locked | Sep 22 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | Sep 17 2025 |
| Stephens & Co. |
Locked
➜
Locked
|
Locked | Sep 15 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Sep 04 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Dec 19 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Barclays:
Locked
➜
Locked
|
Sep 23 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Sep 23 2025 |
|
Locked
Stephens & Co.:
Locked
➜
Locked
|
Sep 22 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
Sep 17 2025 |
|
Locked
Stephens & Co.:
Locked
➜
Locked
|
Sep 15 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Sep 04 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Dec 19 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
